View all veterinary jobs
Pfizer Animal Health, maker of the equine wormers Equest & Equest Pramox, has launched Stable Mate, a new app to help horse owners manage their daily equine healthcare regime and get maximum enjoyment from their horse.
Pfizer says the new app has been described by testers as 'undoubtedly the best equestrian electronic management system you could wish for'. It includes an organiser in which to keep horses' records and details of their management requirements. It also includes Track My Ride, a GPS mapping and exercise planning service, and a news feed direct from Horse & Hound.
Stable Mate allows users to keep records for up to six horses on their iPhone. They just need to enter the information needed to keep track of each horse's health routine, including worm control, vaccinations, dentistry, farriery and feeding regime. The app then creates a calendar of events, appointments and reminders designed to make it easy for owners to keep their horse's essential healthcare needs on course.
Records can be passed to a yard manager or friends when the owner goes on holiday, making a temporary transfer of care straightforward. Stable Mate also offers general equine health advice, from the essentials of pasture management to understanding vaccination protocols.
Track My Ride is a GPS navigation system that allows owners to map the route, duration and speed of each ride. Pfizer says it's a great device for planning and monitoring exercise programmes, that owners can use it to explore new hacking routes safely and that they'll never have to worry about finding their way back to their horse box again when hunting or doing a long distance ride. Details of each ride are stored in a history log and can be shared with friends through social media.
Paul Blanc, Pfizer's equine brand manager said: "We have tried to develop an app that is all about the horse and their owner, making it as easy as possible for owners to keep their equine health care on track as well as add to the fun and pleasure with their horse. Stable Mate has well and truly surpassed our expectations. We hope that owners and riders find Stable Mate useful and enjoyable."
Stable Mate is currently available only for iPhone with Android and Blackberry coming soon.
Stable Mate is available free from the iPhone App Store http://itunes.apple.com/us/app/stable-mate/id532341393?ls=1&mt=8. To find out more visit www.wormingyourhorse.info.
Pfizer Animal Health has launched Zylexis for horses, the first and only immunomodulator licensed in the UK to reduce the clinical signs of equine respiratory disease associated with over-crowding and stress.
Zylexis contains inactivated parapox ovis virus (iPPOV), a super-antigen which Pfizer says boosts a horse's immune system to reduce the effects of infectious respiratory disease1,2 - bridging the gap between potential and performance.
According to the company, Zylexis acts by stimulating the horse's non-specific immune system, inducing antiviral interferons and interleukins and stimulating innate immune cells. In this way it bridges the gap until the horse's adaptive immune system can develop a pathogen-specific response.3-5
Pfizer highlights research which has shown a 40.3% reduction in the clinical signs and duration of respiratory disease in young horses under conditions of crowding and stress and a significant reduction of purulent nasal discharge when using Zylexis.6,7 No local or systemic adverse events were observed in a 999 dose study.8
Wendy Talbot, National Veterinary Manager at Pfizer, said: "Zylexis has been licensed in the States and in Germany for a number of years. We believe Zylexis plays a pivotal role in helping to minimise the severity of respiratory disease outbreaks in these countries, therefore helping to maintain performance potential. It's a very welcome addition to the medicine box of UK vets."
The administration of Zylexis is recommended as a course of three single dose intramuscular injections on days 0, 2 and 9. The first dose should be administered shortly before the over-crowding or stressful situation.
References
Pfizer Animal Health's Equine Herpes Virus (EHV) vaccine (Duvaxyn EHV 1,4) has been rebranded Equip EHV 1,4).
Pfizer says that EHV is carried by most horses in the UK1 and can cause respiratory disease, abortion and more rarely neurological disease. However, it is the more common sub-clinical infections that pose the most apparent issue for the competition client, with the associated loss of performance and the potential effect on the health of the whole yard.
Once infected with EHV, a horse can harbour the virus throughout its life and potentially shed the disease to other animals without showing any outward signs. According to the company, vaccinating helps to minimise the severity of the disease itself and importantly, can also help to reduce the amount of infective virus that is shed to other in-contact horses.
Equip EHV 1,4 is given as a primary course of two vaccinations, 4-6 weeks apart followed by a single dose every six months. It can also be used as an aid in the control of EHV-1 abortion - pregnant mares should be vaccinated with a single dose during each of the 5th, 7th and 9th months of pregnancy.
For further information on Pfizer's EHV campaign, to obtain literature for your practice or to book a talk for your clients contact your Pfizer Account Manager or Pfizer Animal Health, Walton Oaks, Tadworth, Surrey KT20 7NS.
Reference
1. Eddington et al. Equine Vet. J. 1994; 26 (2): 140-142.
Pfizer Animal Health, maker of the equine wormers Equest and Equest Pramox, has unveiled www.wormingyourhorse.info, a new website which aims to make it easier for horse owners to understand and follow the most up-to-date principles of sustainable worm control.
Based on the company's Manage, Test, Plan, Dose campaign, Pfizer says the new website is designed to take the confusion out of equine worm control with clear, logical and easy-to-understand guidance and advice.
The four main sections use diagrams and text to explain how and why it's important to manage the worm challenge on the pasture; the role of faecal worm egg counts (FWECs); how history and management play a part in planning the best worm control programme and how to choose and use the right wormer at the right time of year.
There's an interactive and educational parasite page that shows the parasites that can affect the health of your horse. There are click through buttons on parts of the horse's anatomy revealing details about the appearance of each particular parasite, their lifecycle and the symptoms they can cause. In addition there's a section on frequently asked questions which provides no-nonsense answers to some of the most commonly asked questions about worm control.
Paul Blanc, Pfizer's equine brand manager said: "In developing our new website we have listened carefully to what horse owners really want and need to know. The result is a source of plain-speaking, unbiased facts and advice, providing horse owners with the most current thinking on sustainable worm control in a format they can really identify with."
Pfizer Animal Health and Central Veterinary Services are collaborating in a new venture to create a unified National Benchmarking Database open to all veterinary practices.
In what it says is an unprecedented move, Pfizer will integrate 15 years' worth of data from its Performance Index practice benchmarking service (formerly known as the Fort Dodge Index) with that of the Central Veterinary Services' Management Analysis Indices (MAI). These two benchmarking services have been in co-existence for a number of years, each using different databases. Combining the data from the participating practices within each benchmarking service will create a database of almost 300 practices, representing in excess of 10% of all UK companion animal and mixed practices. This, says the company, will provide a more accurate and relevant benchmarking of UK companion animal practice performance.
The first combined reports from this new National Database will be available in May providing a comprehensive analysis for the first quarter of 2012. For Performance Index practices, this will be available via a new web portal.
Participating practices will continue to access their reports and services independently via their respective portals for PI and MAI, but will benefit from the larger database providing greater accuracy, granularity and relevance of exactly who a practice chooses to benchmark itself against. This, in turn, should provide all participating practices with an even better understanding of both their critical success factors and where there are clear opportunities for growth. Pfizer says that as ever, practice data confidentiality will be guaranteed for all subscribing practices.
Ned Flaxman, Director Business Innovation, at Pfizer Animal Health said: "We have recognised that what veterinary practices really need is to be far more specific about who they benchmark themselves against. There is little relevance to a rural mixed practice in the Lake District employing 3 full time vets (FTVE) benchmarking themselves against a large 5 FTVE companion animal practice in the centre of Manchester - you are comparing apples and pears! My vision for creating the National Database was really to increase the business benefits of practice benchmarking and enable practices to compare apples with apples. With the new system, the large urban practice in Manchester should be able to compare its performance against other urban practices in the North of England employing 5FTVE!
"To ensure practices have accurate and relevant data from which to make informed decisions to grow and thrive in these turbulent conditions, the creation of a single national benchmarking database is the only sensible solution. Although we are effectively levelling the playing field by enabling other veterinary suppliers to offer benchmarking, we believe it is the right thing to do for veterinary practices and the market as a whole. For Pfizer Animal Health, the needs of our veterinary clients are the driving force for our business decisions, veterinary support services and product development."
Martin Barrow, Managing Director of Central Veterinary Services said: "We fully agree that a single benchmarking database is the right solution for the market. The creation of this National Database, open to all practices irrespective of their supplier, will provide the participants with unique tools to give them powerful insights for their practices' future continued success.
"MAI and the Performance Index have competed with each other for years and provided a very useful added value service for their respective subscribers but when we were approached to integrate the two databases, we immediately saw the bigger picture and recognised the significant benefits this could bring to a wider audience of UK veterinary practices.
"The national database uses open standards for data collection and data is accepted from all practices irrespective of which practice management system they use. We believe it is the right thing to do for veterinary practices and brings significant benefits to the whole veterinary profession."
Practices are urged to subscribe to the PI or MAI services either independently or through one of their practice development partners. Although run from a common database each service will continue to be provided with its own unique features.
For further information on Performance Index practices should contact their Pfizer Account Manager, email Pfizer at Vetsupportplusuk@pfizer.com.
For further information on MAI, practices should contact Central Veterinary Services at mai@centralvet.com, or telephone 01359 245310
Pfizer Animal Health has launched PrintRoom, an online printing service to help equine practices deliver high quality communications to their clients, to support the company's Equip range of equine vaccines.
PrintRoom can be used to produce customised vaccination reminder cards, invitations, letterheads, stable name sheets, and more.
You can choose from a palette of designs, images and colours and can also upload your own logos and images to tailor your client communications to your preferred style.
PrintRoom has a MailMerge option to pre-address all your mailings and you can pay for postage and set the date of despatch online, to help ensure boosters are administered on time and passports stay up to date.
Paul Blanc, Equine Brand manager at Pfizer said: "Good communication with your clients plays a vital role in maintaining vaccination compliance and retaining and gaining business. Our print room service makes it easy to produce a broad range of customised practice marketing materials to a very professional standard that stand out from the crowd."
For further information visit http://www.pfizerprintroom.com/, call 0845 6027439 or contact your Pfizer Account Manager.
Pfizer Animal Health is advising vets and horse owners to be on guard against the threat of West Nile Virus (WNV) in the UK, following a spate of outbreaks of the disease in several European countries this year.
West Nile Virus has recently made headline news because of a human outbreak in Greece which resulted in a number of deaths. Outbreaks have also occurred in Russia, Romania and Italy during 2010. West Nile Fever is a viral disease transmitted by mosquitoes, which carry the virus after biting infected birds. Primarily occurring between July and October, in line with typical peak activity of mosquitoes, it can have serious consequences on human and equine health, with severe cases resulting in fatal neurological disease.
There is no cure, though supportive treatment can aid recovery. However if the disease progresses to a state where the animal is not able to stand up, their chance of survival is considered low. Prevention of infection is difficult, but any steps that reduce mosquito numbers or the likelihood of horses and people being bitten may help to reduce the risk in areas where the disease is present. However, the only way to reduce the risk of an individual horse developing disease due to WNV is through vaccination.
Ben Gaskell, Pfizer's equine veterinary advisor said: "West Nile Virus may well become a very real threat to both horses and humans in Northern Europe. It is important for vets, horse owners and infectious disease experts to work together to mitigate its impact in the event of the virus becoming endemic across Europe. The rapid spread of the disease across North America is an illustration of what could potentially happen in Europe and it is important to remember there is no curative treatment - the only way to prevent clinical disease in horses is by vaccination."
Pfizer Animal Health supports the PrEquID (Prevention of Equine Infectious Disease) group, which consists of internationally recognised equine and infectious disease experts. The group was formed to develop guidelines on the prevention and control of a number of equine infectious diseases, on a global basis.
Klaus Osterrieder, Professor and Chair in the Institut für Virologie in the Veterinärfakultät at Freie Universität Berlin, Germany and a member of the PrEquID group advises: "Horse owners should ask their veterinarian for advice on appropriate prevention measures. Experience has shown that adopting a prudent prevention strategy can be a very effective way of managing this devastating disease."
Further information on WNV is available at www.westnile.eu.
Pfizer Animal Health has launched Vet Support+ a dedicated veterinary business consultancy team with a brief to boost the profitability and productivity of veterinary practices across the UK.
Staffed by a team of seven business consultants who have undertaken academic and practical training to add to their experience in the veterinary industry, Vet Support+ will offer tailored support to practices in a format which aims to offer flexibility and a rapid return on investment. The services range across the three critical areas of business operations, client relations and staff management. Consultants will initially focus on supporting practices operating in the companion animal sector, extending their service to the dairy sector early in 2011.
According to Pfizer, the Vet Support+ service has been developed in response to detailed research among practices to understand their requirements for business advice and support. It's launched against a backdrop of continued stagnation in the veterinary sector according to latest data from the Fort Dodge Index benchmark of practice performance. Vet Support+ will operate independently of the pharmaceutical business with no sharing of information or data.
Vet Support+'s consultants are based across the UK in order to be convenient for practices in any part of the country.
The team is headed by Laura Jenkins, who has held a range of senior roles at Pfizer UK. Laura said: "Many vets working in practice relish the clinical side of their work for which they have trained so hard. It can therefore come as a shock to many that they also find themselves responsible for running the business side of the practice for which they may have received virtually no guidance during their training. They have a real need for objective, practical advice they can trust, which is based on a detailed knowledge of the market. Many also appreciate 'hand-holding' and coaching through the tough process of making changes required within the practice in order to put it on a more stable and successful footing. The continuing challenges of the economic climate make it imperative that practices take bold steps now to ensure not only that they're able to withstand the continued recession but are well-positioned to take advantage of the upturn when it comes.
"Our Vet Support+ consultants are highly experienced in the veterinary market and have received very positive feedback from the practices they've worked with during a pilot of the service. They're focused on demonstrating significant value to their clients and achieving early results on the bottom line. They'll be looking to build a close relationship with their client practices, acting as a coach and 'critical friend' as they help them plan for a successful and profitable future."
For further information on the Vet Support+ service please contact Laura Jenkins on 01737 330705.
Pfizer Animal Health is reminding horse owners of the importance of treating encysted small redworm larvae this autumn.
According to the company, these hidden, dormant parasites can account for up to 90% of the redworm burden in a horse (1). Furthermore, encysted small redworm larvae won't show up in a faecal egg count (FEC). Even if a horse has shown a negative or low count it could still be harbouring several million harmful larvae, hidden within the gut wall (2)
Encysted small redworm are a potential time bomb, with the ability to survive inside a horse for up to two years. They usually 'wake-up' in the late winter or early spring, developing and emerging from the gut wall all at the same time. Such a sudden mass emergence can cause a disease syndrome known as 'larval cyathostominosis', causing diarrhoea and colic with up to a 50% mortality rate (2). Treating encysted small redworm successfully in the late autumn or early winter is vitally important in order to prevent this serious risk.
Pfizer says that Moxidectin, the key ingredient of EQUEST, is recognised as the only single dose treatment for encysted small redworm. It has been shown to kill the larvae in-situ, without resulting in severe inflammation of the gut wall that other multi-dose treatments may cause (3). In addition, Moxidectin is licensed for persistent activity against small redworm over two weeks, killing larvae ingested as the horse grazes for up to two weeks after treatment.
Ben Gaskell, Pfizer's veterinary advisor said: "A responsible and sustainable worming programme involves good pasture management, regular diagnostic tests and targeted worming, carefully planned using specialist advice. However, it is also vital to remember the danger of encysted small redworm. Even if a horse's FEC is clear, there could still be a significant encysted small redworm burden that must be treated properly every year in late autumn / early winter."
1) Bairden K. et al (2001) Veterinary Record 148, 138-141 2) Dowdall S.M.J. et al (2002) Veterinary Parasitology 106, 225‑242 3) Steinbach T. et al (2006) Veterinary Parasitology 139, 115‑131
Pfizer Animal Health has launched a dedicated Equine Business Unit to provide a higher level of service and a comprehensive range of products to equine vets across the UK.
Created following the merger with Fort Dodge, the Pfizer Equine Business Unit is headed by Ben Lacey MA Vet MB MRCVS, who has previously held both technical and sales roles at Pfizer. Ben and his team have a brief to offer a breadth of product, support and flexibility not previously available to equine vets.
The product range offered by the Pfizer Equine Business Unit includes the Equest range of parasiticides; the Duvaxyn vaccines for Equine Herpes Virus, West Nile Virus and Rotavirus and products such as Equimidine and Torbugesic. Also offered are existing Pfizer brands such as the Equip vaccine range, the antibiotic Excenel Sterile Powder, the NSAID Rimadyl for Horses and Depo-MedroneV.
Five experienced account managers with a strong track record in the equine sector have been appointed by Pfizer to build relationships with equine vet practices on a regional basis. They are:
South East England Mark BakerWest Midlands, Cheshire, Wales Laurie MayEast Anglia, East Midlands Penny McCannSouth West, South Wales Anna CunninghamThe North, Scotland Alexandra Cox
Ben Lacey said: "Building our new team and combining the highly regarded products offered previously by both Fort Dodge and Pfizer has proved a stimulating process. We've also worked closely with many of our existing practice customers to look at how we can develop the service we provide to them.
"We're now able to offer a product range which I believe is unrivalled in the market and a highly committed team of equine professionals, who share a vision and passion for equine health. We're looking forward to building our business with both existing and new customers in the months ahead."
Pfizer Animal Health has announced that its Dental Leadership programme is now available on-line at www.dental-leadership.co.uk.
The course is offered under the 'Pfizer Academy' umbrella and has previously been available in hard copy for over five years. Almost 1000 vets and nurses have tackled the course since inception and it is anticipated that the on-line version will prove to be equally successful.
Annelies Hall is the AntirobeTM Product Manager at Pfizer Animal Health. She said: "High quality CPD can sometimes be difficult to fit into a busy schedule. We recognised that the open learning format was attractive to vets and nurses because it was flexible and could be fitted around a demanding job. The teaching of dentistry to students has become much higher profile lately but many older graduates feel it is an area where they can learn more, and due to the prevalence of dental disease, can immediately put their learning into action."
A separate course is available for veterinary surgeons and veterinary nurses and the course contributes 10 hours of CPD time. Learning is assessed through an on-line multiple choice examination and a certificate can be printed off when the pass mark is achieved. The course was developed by Pfizer Animal Health in association with Norman Johnston BVM&S, Dipl.AVDC, Dipl.EVDC, MRCVS, American & European Specialist in Veterinary Dentistry and covers topics such as anatomy, preventative treatment, periodontal disease, the dental workplace, equipment, radiography, economics and marketing veterinary dentistry.
Lisa Milella, President of the British Veterinary Dental Association said: "Dentistry is one of the most important aspects of veterinary healthcare alongside vaccination and medical care. Dental procedures should contribute 25% of the daily operating list in every small animal practice but unfortunately less than 5% of clients realise that their pet has a problem, leaving the onus on their veterinary practice to pro-actively identify dental disease."
The course is free of charge and those wishing to enrol are asked to visit www.dental-leadership.co.uk. For any further enquiries call 0870 0056554. The dental leadership website also contains details of the 2009 Pfizer Dental Bursary for veterinary nurses wishing to study for the BVNA Certificate in Dentistry.
Pfizer Animal Health has launched a new range of diabetes support materials, including a DVD, post-prescription leaflet and home recording chart for owners of diabetic cats and dogs; a vet detailer, poster and blood glucose monitoring chart for the practice.
The company says that diabetes is on the increase in pets, as the level of obesity in cats and dogs escalates. Current estimates put the disease prevalence at 0.32% in the dog population1 with similar levels suggested for cats with some being as high as 1 in 1002. With increasing economic pressures and busy lifestyles, many owners are reluctant to take on the challenge of a diabetic pet, yet most pets respond extremely well to treatment.
Susan Mitchell, Insuvet® Product Manager at Pfizer Animal Health, believes that communication is key: "Helping owners to understand that treatment need not be difficult and that routines can be flexible enough to fit in with their lifestyles is critical. Time and time again it has been shown that cost is not always the primary consideration when it comes to treating the pet that is viewed as a much loved member of the family.
"Ensuring that owners understand exactly what will be expected of them is likely to be pivotal to the success of diabetes management than might first be assumed. Our new range of support material focuses on that need and takes the owner right the way through the process, from that initial diagnosis when decisions hang in the balance, to improving compliance by providing all the tools necessary for effective day to day management of the disease."
The new support materials include a DVD that explains all that clients need to know about the condition. This, says Pfizer, is the ideal choice after initial diagnosis, to reinforce and support the dialogue that takes place in the clinic environment. Shock, fear and confusion may mean that many owners will simply fail to take in all that their vet has to tell them after the initial diagnosis. This, in turn may prevent the owner from making an objective decision about their pet's future.
Once emotions have settled the client can watch the DVD in their own home, start to approach the future more rationally and decide what adaptations may have to be made. A post prescription leaflet is available to provide reassurance about the daily routine of monitoring a diabetic pet and a home recording chart to aid long-term compliance.
Of course, diabetic patients can be just as challenging in the practice environment so a comprehensive vet detailer is available along with blood glucose monitoring charts, a poster detailing what to do in a keto-acidotic emergency, a veterinary nurse discharging list and a clinic letter.
For further information on the Insuvet® range or to request support materials for diabetic clinics or individual patients, vets and nurses should contact their Pfizer Business Account Manager. For any technical questions about the Insuvet range call the Pfizer Animal Health Technical Support Line on 0845 3008034.
Two veterinary nurses are looking forward to expanding their career horizons thanks to a bursary from Pfizer Animal Health.
Donna Buzzeo RVN and Serena Fox (who holds an Australian certificate in Veterinary Nursing) were judged to be the strongest candidates because of the commitment they had already shown to developing their skills in dentistry. The bursary, worth £1500 each will allow both nurses to enrol for the BVNA Certificate in Dentistry course and covers course and examinations fees as well as a substantial contribution towards travel or accommodation during the residentially based parts of the course.
Donna Buzzeo works at Mulberry Court Vets in Sudbury with vet Gerhard Putter who is studying towards a diploma with the European College of Veterinary Dentistry. Since the practice has a special interest in dentistry and oro-facial surgery, Donna has been able to develop her skills further and she is currently running a successful programme of nurse clinics promoting oral health. Both Gerhard and Donna have completed the AntirobeTM Dental Leadership courses for vets and nurses respectively. This distance learning course is available through Pfizer's Territory Managers and is recognized as providing 10 hours of CPD time.
Serena Fox has been working towards increasing her knowledge of dentistry for some time while working at the Well Pet Clinic in London. She has attended a dentistry workshop and given talks to other staff members based on her new learning and in 2008 attended the Nursing Masterclass in Dentistry at BSAVA Congress where she found out more about the Certificate.
Marcon Tigges, Antirobe Product Manager commented, "For many years now we have awarded this bursary to champion the cause of further learning in dentistry and also to encourage nurses who want to progress their careers. We wish Serena and Donna the best of luck with their course."
For further information on the Antirobe Dental Leadership course nurses and vets can contact their Pfizer Business Account Manger.
Pfizer Animal Health has launched Dexdomitor, a new, advanced form of the popular sedative /analgesic Domitor (medetomidine). According to Pfizer, Dexdomitor contains only the right-handed enantiomer (dexmeditomidine) which is responsible for the beneficial pharmacological effects of the meditomidine molecule. By removing the left-handed enantiomer (levomedetomidine) from the original racemic mixture the same sedative and analgesic effects can be achieved with a lower metabolic load, less potential for interaction with other drugs and half the active substance. According to Dr Jo Murrell, Senior lecturer in veterinary anaesthesia in Bristol Vet School, the use of dexmedetomidine has a number of advantages in terms of veterinary use: "Because dexmedetomidine had to undergo a lot of safety studies to get market authorisation in humans, we have a huge amount of cardiovascular data about the effects of dexmedetomidine in dogs," she said. "That means we know very precisely the effects of dexmedetomidine on cardiac output, on organ blood flow and the changes in blood flow to vital organs such as the heart and brain." Dr Murrell recommends that practices that are currently using Domitor should consider switching to Dexdomitor when it becomes available. "You won't notice any disadvantages as a result of the switch, but you may well notice that the effects of dexmedetomidine are more reliable compared to medetomidine, and you may notice some benefits in terms of recovery from anaesthetic combinations."